These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3065422)

  • 1. Inhibition of phenolic glycolipid-I synthesis in extracellular Mycobacterium leprae as an indicator of antimicrobial activity.
    Harris EB; Franzblau SG; Hastings RC
    Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):588-91. PubMed ID: 3065422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro effects of antimicrobial agents on Mycobacterium leprae in mouse peritoneal macrophages.
    Ramasesh N; Krahenbuhl JL; Hastings RC
    Antimicrob Agents Chemother; 1989 May; 33(5):657-62. PubMed ID: 2665640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of ATP assay for in vitro drug screening testing against human derived M. leprae.
    Katoch VM; Katoch K; Shivannavar CT; Sharma VD; Patil MA; Bharadwaj VP
    Indian J Lepr; 1989 Jul; 61(3):333-44. PubMed ID: 2671179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system.
    Franzblau SG
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2115-7. PubMed ID: 2694952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid in vitro metabolic screen for antileprosy compounds.
    Franzblau SG; Hastings RC
    Antimicrob Agents Chemother; 1987 May; 31(5):780-3. PubMed ID: 3300539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy.
    Bach MA; Wallach D; Flageul B; Hoffenbach A; Cottenot F
    Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):256-67. PubMed ID: 3522769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of Mycobacterium leprae in macrophages.
    Ramasesh N; Hastings RC; Krahenbuhl JL
    Infect Immun; 1987 May; 55(5):1203-6. PubMed ID: 3552993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM; Dimova V
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug resistance of Mycobacterium leprae].
    Pattyn SR
    Acta Leprol; 1986; 4(3):279-87. PubMed ID: 3551466
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis and antileprosy activity of some dialkyldithiocarbamates.
    Makarov V; Riabova OB; Yuschenko A; Urlyapova N; Daudova A; Zipfel PF; Möllmann U
    J Antimicrob Chemother; 2006 Jun; 57(6):1134-8. PubMed ID: 16595643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of hypoxanthine incorporation in purified suspensions of Mycobacterium leprae: a suitable method to screen for anti-leprosy agents in vitro.
    Wheeler PR
    J Med Microbiol; 1988 Mar; 25(3):167-74. PubMed ID: 3279214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidation of palmitic acid by Mycobacterium leprae in an axenic medium.
    Franzblau SG
    J Clin Microbiol; 1988 Jan; 26(1):18-21. PubMed ID: 3125213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competency of human-derived Mycobacterium leprae to use palmitic acid in the synthesis of phenolic glycolipid-I and phthiocerol dimycocerosate and to release CO2 in axenic culture.
    Shannon EJ; Harris EB; Haile-Mariam HS; Guebre-Xavier M; Frommel D
    Lepr Rev; 1992 Jun; 63(2):101-7. PubMed ID: 1640777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chemotherapy on antibody levels directed against PGL-I and 85A and 85B protein antigens in lepromatous patients.
    Drowart A; Chanteau S; Huygen K; De Cock M; Cartel JL; De Bruyn J; Launois P; Yernault JC; Van Vooren JP
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):29-34. PubMed ID: 8326178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysical optima for metabolism of Mycobacterium leprae.
    Franzblau SG; Harris EB
    J Clin Microbiol; 1988 Jun; 26(6):1124-9. PubMed ID: 3290244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
    Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
    Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeling of Mycobacterium leprae lipids within schwannoma cells, a potential drug screening system.
    Mistry Y; Antia NH; Mukherjee R
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1444-7. PubMed ID: 1929306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae.
    Shepard CC
    Int J Lepr Other Mycobact Dis; 1982 Mar; 50(1):96-101. PubMed ID: 7042616
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
    Dhople AM
    Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of monocyte oxidative response by phenolic glycolipid I of Mycobacterium leprae.
    Vachula M; Holzer TJ; Andersen BR
    J Immunol; 1989 Mar; 142(5):1696-701. PubMed ID: 2537362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.